FDA Accepts Shorla’s NDA for SH-201 to Treat Leukemia and Other Cancers

FDA has granted Shorla Oncology’s second FDA acceptance for a New Drug Application (NDA) for SH-201, the first palatable oral liquid form of a chemotherapeutic agent designed to treat leukemia and other cancers.

Read more at: Article